Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01715233 · ClinicalTrials.gov registry record · Phase 2
Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01715233 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 27 participants.
The verdict
NCT01715233, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
To estimate and compare the response rates in patients treated with mDCF based on methylation status of CHFR.
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Fluorouracil
- DRUG Leucovorin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-12 |
| Est. Completion | 2017-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01715233
The ClinicalTrials.gov registry entry for NCT01715233 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT01715233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01715233 about?
NCT01715233 is a clinical study titled "Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.". To estimate and compare the response rates in patients treated with mDCF based on methylation status of CHFR.
What is the current status of trial NCT01715233?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2012-12. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01715233?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Fluorouracil (DRUG), Leucovorin (DRUG).
Who is sponsoring clinical trial NCT01715233?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.